<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628250</url>
  </required_header>
  <id_info>
    <org_study_id>SH-MIS</org_study_id>
    <nct_id>NCT01628250</nct_id>
  </id_info>
  <brief_title>Laparoscopic Complete Mesocolic Excision on Colon Cancer</brief_title>
  <acronym>LCME</acronym>
  <official_title>Clinical Research on the Efficacy and Feasibility of Laparoscopic Complete Mesocolic Excision on Colon Cancer: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bo Feng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic complete mesocolic excision is a concept that using laparoscopic surgery
      technique to perform a resection for colon cancer. Besides, the segment of the colon
      containing the tumor, the resection area should include an intact mesocolon as an envelope to
      encase the possible route for metastasis. The routes include blood vessels, lymphatic drain
      and etc. Such hypothesis predicts better histopathological and higher oncological results
      which turns into better survival rate and better quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathological Outcomes Obtained Through the Surgeries</measure>
    <time_frame>14 days after the surgery</time_frame>
    <description>number of lymph nodes retrieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>3 years after the surgery</time_frame>
    <description>The follow up to the patients after the surgery to evaluate the oncological results of the technique</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Operation Finding</condition>
  <condition>Complications</condition>
  <condition>Pathology</condition>
  <condition>Quality of Life</condition>
  <condition>Neoplasms Recurrence</condition>
  <arm_group>
    <arm_group_label>laparoscopic complete mesocolic excision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D3 laparoscopic colectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized group of patients receiving laparoscopic colectomy with D3-resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic complete mesocolic excision</intervention_name>
    <description>laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.</description>
    <arm_group_label>laparoscopic complete mesocolic excision</arm_group_label>
    <other_name>laparoscopic CME</other_name>
    <other_name>Complete Medial Approach (CMA)</other_name>
    <other_name>Hybrid Medial Approach (HMA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D3-laparoscopic colectomy</intervention_name>
    <description>D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.</description>
    <arm_group_label>D3 laparoscopic colectomy</arm_group_label>
    <other_name>D3 laparoscopic colectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed colon cancer

          -  Signed consent

        Exclusion Criteria:

          -  History of malignancy

          -  Intestinal obstruction or perforation

          -  Evidence of metastasis by preoperative examinations

          -  Deformity of spine

          -  Emergency case

          -  BMI &gt; 29
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Feng, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Minimally Invasive Surgery Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiaotong University school of medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <results_first_submitted>November 7, 2015</results_first_submitted>
  <results_first_submitted_qc>May 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2016</results_first_posted>
  <last_update_submitted>May 21, 2016</last_update_submitted>
  <last_update_submitted_qc>May 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bo Feng</investigator_full_name>
    <investigator_title>Research chair of MIS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laparoscopic Complete Mesocolic Excision</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
laparoscopic complete mesocolic excision: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.</description>
        </group>
        <group group_id="P2">
          <title>D3 Laparoscopic Colectomy</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with D3-resection
D3-laparoscopic colectomy: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laparoscopic Complete Mesocolic Excision</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
laparoscopic complete mesocolic excision: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.</description>
        </group>
        <group group_id="B2">
          <title>D3 Laparoscopic Colectomy</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with D3-resection
D3-laparoscopic colectomy: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histopathological Outcomes Obtained Through the Surgeries</title>
        <description>number of lymph nodes retrieved</description>
        <time_frame>14 days after the surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laparoscopic Complete Mesocolic Excision</title>
            <description>Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
laparoscopic complete mesocolic excision: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.</description>
          </group>
          <group group_id="O2">
            <title>D3 Laparoscopic Colectomy</title>
            <description>Randomized group of patients receiving laparoscopic colectomy with D3-resection
D3-laparoscopic colectomy: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathological Outcomes Obtained Through the Surgeries</title>
          <description>number of lymph nodes retrieved</description>
          <units>nodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="5.8"/>
                    <measurement group_id="O2" value="19.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rate</title>
        <description>The follow up to the patients after the surgery to evaluate the oncological results of the technique</description>
        <time_frame>3 years after the surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Laparoscopic Complete Mesocolic Excision</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
laparoscopic complete mesocolic excision: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.</description>
        </group>
        <group group_id="E2">
          <title>D3 Laparoscopic Colectomy</title>
          <description>Randomized group of patients receiving laparoscopic colectomy with D3-resection
D3-laparoscopic colectomy: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>vessel-related complication</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bo Feng</name_or_title>
      <organization>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</organization>
      <phone>021-64458887</phone>
      <email>fengbo2022@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

